Bioventus Introduces Broadened Portfolio for Orthopaedic Surgeons

Bioventus Introduces Broadened Portfolio for Orthopaedic Surgeons

LAS VEGAS, NV – March 25, 2015 – Bioventus, a leader in orthobiologic solutions, today announced the introduction of its broadened product offering for orthopaedic surgeons. The company now has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical which will be on display in booth #5437 at the Annual Meeting of the American Academy of Orthopaedic Surgeons March 25-27 in the Venetian Sands EXPO.

The new Bioventus Surgical line of products includes OsteoAMP®, allogeneic bone with endogenous growth factors, which uses a proprietary process designed to retain the bone’s natural growth factor complement. OsteoAMP may be used for spinal fusion and orthopaedic trauma applications and comes in three distinctive formats: granules, compressible sponges, and putty. Additional products are expected to be added to Bioventus Surgical in the near future.

Bioventus Active Healing Therapies consists of products that allow patients to resume active lives using their bodies own processes to heal faster or reduce pain. Products include the EXOGEN® Ultrasound Bone Healing System - indicated for the treatment of established non-unions and indicated fresh fractures; SUPARTZ® - a joint fluid hyaluronic acid for treatment of pain in the knee due to osteoarthritis (OA) and DUROLANE® - a single-injection joint-fluid based upon a natural, safe and proven technology called NASHA® (stabilized hyaluronic acid) and indicated for the treatment of mild to moderate OA pain in a variety of joints. Hyaluronic acid (HA) is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint.

In addition, Bioventus continues to make solid pre-clinical progress with the bone morphogenetic protein (BMP) assets it acquired from Pfizer in 2013.

“Since its inception in 2012, Bioventus has strived to make a difference by helping patients resume and enjoy active lives,” said Allison London Brown, Vice President, Global Marketing, Bioventus. “This week at AAOS we are excited to share our progress with attendees as we grow our active healing therapies products and develop offerings for the surgical space.”

EXOGEN is manufactured and marketed by Bioventus in multiple countries around the world including the U.S., DUROLANE is not available in the U.S. but is otherwise available worldwide where registered, while both SUPARTZ and OsteoAMP are sold only in the U.S.

About Bioventus

Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company’s innovative products include market-leading devices, therapies and diagnostics that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

For more information on Bioventus visit

.Summary of Indications for Use

The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization. There are no known contraindications for the EXOGEN device. Safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, on fractures due to bone cancer, or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling at or by calling customer service at 1-800-836-4080. A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.

SUPARTZ is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g. acetaminophen. You should not use SUPARTZ if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found here or by calling customer service at 1-800-836-4080.

For the symptomatic treatment of mild to moderate osteoarthritis. DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes. DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to 6 months but results may vary depending on various patient factors. DUROLANE is not approved for sale in the United States.

Bioventus, the Bioventus logo, EXOGEN and OsteoAMP are registered trademarks of Bioventus LLC. SUPARTZ is a registered trademark of Seikagaku Corp. DUROLANE and NASHA are registered trademarks of Galderma S.A.

Media Contact: Thomas Hill   [email protected]